L

LGC Group

Sells oligos, probes, primers, viral materials

Overview

LGC Group provides life sciences tools and solutions, including oligo components, probes, primers, and recombinant viral materials, plus proficiency-testing schemes for areas like food safety. Its products support detection and development in healthcare through mass spectrometry, immunoassays, and nucleic acid chemistry for vaccines, diagnostics, and therapies. The company differentiates itself with a broad portfolio and global testing services that help customers from diagnostics to vaccine development. Its goal is to improve healthcare outcomes and public safety by enabling accurate testing and high-quality scientific tools.

Work here?Claim your company

About LGC Group

Simplify's Rating
Why LGC Group is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

BiotechnologyHealthcare

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

London, United Kingdom

Founded

1841

Get referred to LGC Group

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • DHSC awarded LGC two NIHR lots on 7 October 2026, extending recurring revenue.
  • Fitch kept LGC at B Stable on 7 May 2026, preserving financing access.
  • Axolabs’ Berlin cGMP facility broadens late-stage oligonucleotide manufacturing for pharma customers.

What critics are saying

  • Fitch expects negative free cash flow in FY26-FY27 from capex and restructuring.
  • S&P flagged 12x-13x debt leverage in FY25-FY26, limiting acquisitions and hiring.
  • If Axolabs delays continue, LGC’s leverage stays elevated and refinancing pressure intensifies.

What makes LGC Group unique

  • LGC’s 2027 NIHR contracts secure embedded UK government work through 2032.
  • The 2026 ChromaDex purchase adds 3,000+ reference materials and North American reach.
  • Vaughan’s CAD$100 million synthesis center gives LGC dedicated oligonucleotide and chemistry capacity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Hybrid Work Options
  • Remote Work Options

Growth & Insights and Company News

6 month growth

-6%

1 year growth

-8%

2 year growth

-8%
LGC Group
Oct 27th, 2026
LGC awarded DHSC contracts to support UK health and care research.

LGC awarded DHSC contracts to support UK health and care research. The agreement reinforces LGC's role in delivering high-quality research services to help advance healthcare innovation and improve patient outcomes. London, UK - 26 October 2026 - Leading life sciences company LGC today announced that it has been awarded three contracts by the Department of Health and Social Care (DHSC) to deliver services for the National Institute for Health and Care Research (NIHR). The NIHR powers life-changing research for the health and wealth of the nation, including meeting future needs of the health and care research system. From 1 April 2027, LGC will provide DHSC with NIHR strategic business services as well as commissioning and management of NIHR research infrastructure to support translational, health, public health and social care research. The three contracts will run for an initial five-year period and represent a key part of delivering DHSC's £1.7 billion annual investment in research through the NIHR. LGC has been delivering research management services to DHSC since 2001 and has supported key aspects of DHSC work, such as rapid commissioning of vital research during the COVID-19 pandemic. The award of these contracts builds on the long-standing relationship between the organisations. Together, the contracts form an important part of the next phase of continued support for the NIHR's research infrastructure and services that enable life-changing health and care research. The contracts awarded are: * NIHR Strategic Business Services - including life science industry engagement, intellectual property management, communications and partner engagement, portfolio insight, pandemic preparedness, research inclusion and impact monitoring and evaluation. * NIHR Research Infrastructure - including two contracts to deliver Research Commissioning of Translational and Delivery Infrastructure and Applied, Public Health and Social Care Infrastructure. Ahead of the contracts commencing in April 2027, LGC will work closely with NIHR and partner suppliers to ensure a smooth transition, continuity of services and the ongoing delivery of high-quality research support. Joydeep Goswami, President and Chief Executive Officer at LGC, said: "LGC has had a long and successful track record of supporting NIHR over the past 20 years and LGC Limited is honored to have been selected to continue that strong partnership with DHSC. Through these contracts, LGC Limited will help deliver the infrastructure, commissioning and operational services that underpin health and care research across England. "The awards reflect the strength of our scientific expertise, publicly funded programme delivery capabilities and commitment to research excellence. Together with NIHR and its partners, we look forward to enabling research that improves patient outcomes, strengthens the research ecosystem and delivers lasting societal impact."

Samedan Ltd
Oct 12th, 2026
Trio become latest Symbiosis commercial additions.

Trio become latest Symbiosis commercial additions. Symbiosis Pharmaceutical Services has further strengthened its commercial team with three new appointments. Payal Roychoudhury and Joaquín Pérez Fornieles join the Business Development team supporting growth respectively in APAC and Southern Europe and Annie Shafran joins as Inside Sales Manager. A contract development and manufacturing organisation (CDMO), Symbiosis specialises in the aseptic manufacture and fill-finish of injectable medicines for clinical trials and commercial supply. The Stirling-based business is targetting international growth across the Southern Europe, Asia-Pacific and the Middle East territories. Joanne Anderson, Chief Commercial Officer at Symbiosis, said: "We're delighted to welcome Payal, Joaquín and Annie to the Symbiosis team. Payal and Joaquín will help us build relationships in priority international markets, while Annie's new role will strengthen the support we provide from the first client enquiry. Together, they will help more drug developers access the manufacturing capacity and expertise we have invested strongly in." Based in Glasgow, Roychoudhurywill focus on the Asia-Pacific and the Middle East territories. Fornieles, based in Málaga, Spain, has responsibility for Southern Europe and support for other European and selected markets. Shafran, based in Manchester, joins from LGC where she was a Key Account Manager working with international clients. The appointments follow the recent arrival of Jay Chima as Vice President, Business Development, and Jos Vergeest as Senior Business Development Director. Symbiosis' £26 million expansion programme, has increased its aseptic manufacturing capacity for clinical and commercial supply.

LNEG - Laboratório Nacional de Energia e Geologia
Jul 17th, 2026
LNEG and LGC are organising an international workshop on ocean-inspired strategies at SEA TECH WEEK 2026.

LNEG and LGC are organising an international workshop on ocean-inspired strategies at SEA TECH WEEK 2026. Published on 17 July, 2026 Updated on 17 July, 2026 The National Laboratory for Energy and Geology (LNEG, Lisbon) and the Laboratoire de Génie Chimique (LGC, Toulouse) are organising, as part of SEA TECH WEEK 2026, the workshop 'Marine-Inspired Strategies for Enhancing Materials Durability' (STW40), to be held on the morning of 8 October in Brest, France. SEA TECH WEEK is one of the leading international events dedicated to maritime science and technology, bringing together experts, researchers and companies from across Europe in Brest between 6 and 8 October to discuss innovation in the service of the ocean. This year, Portugal is the guest country for the event, which guarantees free registration for Portuguese participants. The STW40 workshop, one of the workshops proposed and selected for inclusion in the event's official programme, forms part of the ALGAPROTEC project (LGC & LNEG), a bilateral cooperation initiative between France and Portugal, funded by the CNRS IRP programme (International Research Project).

LGC Group
May 1st, 2026
LGC acquires SAFEFOOD 360°, expanding its supply chain assurance offering

The acquisition expands our supply chain assurance offerings, while also supporting compliance with major food safety and supplier management requirements globally.

LGC Group
Feb 26th, 2026
LGC Group strengthens its reference material portfolio and North American reach with the acquisition of the ChromaDex Reference Standards business

LGC Group strengthens its reference material portfolio and North American reach with the acquisition of the ChromaDex Reference Standards business. The acquisition further enhances LGC's ability to support pharmaceutical, food, and testing laboratories with trusted reference materials that underpin safety, quality, and regulatory confidence. London, UK, 26 February 2026. LGC Group, a global leader in life sciences, diagnostics, and analytical solutions, today announced the acquisition of the ChromaDex Reference Standards portfolio from Niagen Bioscience (NASDAQ: NAGE). The acquisition expands LGC's reference materials offering and strengthens its commercial reach across North America. The acquisition brings an established portfolio of phytochemical reference materials for the dietary supplements industry into LGC, enabling direct engagement with a broad base of laboratory customers and strengthening LGC's ability to support pharmaceutical companies, testing laboratories, and food producers operating in regulated markets. Bruno Rossi, EVP & General Manager, LGC Standards, said: "The ChromaDex standards portfolio further enhances LGC's ability to support our pharmaceutical customers, testing laboratories, and food producers. Building on LGC's position as a world leader in reference materials and analytical standards, this acquisition expands our North American commercial reach and further supports customers in generating reliable data that safeguards product integrity and confidence across global supply chains." For over 25 years, the ChromaDex Reference Standards portfolio has been built on deep expertise in phytochemical characterisation and analytical verification. The portfolio includes over 3,000 phytochemical reference materials, spanning major classes such as alkaloids, flavonoids, terpenes, carotenoids, organic acids, stilbenoids, vitamins, and select botanicals and plant-based compounds. These materials are widely used to support ingredient verification, method development, authenticity testing, contamination detection, and routine quality control across complex global supply chains. Rob Fried, CEO of Niagen Bioscience, remarked, "This transaction reflects our disciplined focus on what we do best - advancing NAD+ science and delivering clinically proven, patented Niagen(R) solutions across consumer and clinical channels. Selling Reference Standards to LGC is a meaningful step in simplifying our business and ensuring we are allocating capital and talent toward the highest-impact opportunities for shareholders." The acquisition of the ChromaDex Reference Standards portfolio demonstrates LGC's commitment to providing trusted reference materials and measurement solutions that reinforce product safety, quality, and regulatory confidence, advancing its mission of Science for a Safer World. LGC is a global leader in life sciences, diagnostics, and analytical solutions. LGC Group work with partners around the world to address some of society's most important challenges, from diagnosing disease and enabling new treatments to supporting food security and protecting public health. Its science supports discovery, enables better health outcomes and helps safeguard the integrity of food, water, medicines and the environment. Every day, LGC Group provide the components, standards and services that laboratories, manufacturers and regulators rely on to make confident, evidence-based decisions. With operations in 14 countries and more than 180 years of scientific expertise, its work supports public health and sustainability at a global scale. From improving the accuracy of medical testing and verifying the safety of food products, to helping scientists develop the next generation of medicines, its solutions are trusted by customers in more than 170 countries. For further information please contact: Customer contact: Richard Pembrey Sales Director, LGC Standards +1 603 851 2834 Media contact: Magda Bartoszewicz Director Corporate Brand and Communications, LGC Group +44 7408 850 514

Recently Posted Jobs

Sign up to get curated job recommendations

LGC Group is Hiring for 91 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs